Limits...
Infliximab partially alleviates the bite force reduction in a mouse model of temporomandibular joint pain.

Kim SH, Son CN, Lee HJ, Cho HC, Jung SW, Hur JA, Baek WK, Jung HR, Hong JH - J. Korean Med. Sci. (2015)

Bottom Line: From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05).However, the degree of reduction in BF was less remarkable compared to that in the CFA group.The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea. ; Pain Research Center, School of Medicine, Keimyung University, Daegu, Korea.

ABSTRACT
Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

No MeSH data available.


Related in: MedlinePlus

Temeporomandibular joint of control (A), infliximab group (B), and CFA group (C) (H&E, ×40). The synovial membrane of control group (D) is smooth and lined by 1-2 synovial cells (H&E, ×400). In infliximab group (E), synovial membrane is lined by 2-3 cells (arrowhead) and shows moderate degree of chronic inflammation (H&E, ×400). The CFA group (F) shows severe inflammation and marked synovial hyperplasia which shows irregularly piled synovial cells (arrows) (H&E, ×400).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4414638&req=5

Figure 4: Temeporomandibular joint of control (A), infliximab group (B), and CFA group (C) (H&E, ×40). The synovial membrane of control group (D) is smooth and lined by 1-2 synovial cells (H&E, ×400). In infliximab group (E), synovial membrane is lined by 2-3 cells (arrowhead) and shows moderate degree of chronic inflammation (H&E, ×400). The CFA group (F) shows severe inflammation and marked synovial hyperplasia which shows irregularly piled synovial cells (arrows) (H&E, ×400).

Mentions: We analyzed the TMJ histology in the control, infliximab and CFA group. Normal, well preserved synovial lining was observed in the control group. CFA group demonstrated severe inflammation with marked synovial hyperplasia while infliximab group with moderate degree of chronic inflammation (Fig. 4A-F).


Infliximab partially alleviates the bite force reduction in a mouse model of temporomandibular joint pain.

Kim SH, Son CN, Lee HJ, Cho HC, Jung SW, Hur JA, Baek WK, Jung HR, Hong JH - J. Korean Med. Sci. (2015)

Temeporomandibular joint of control (A), infliximab group (B), and CFA group (C) (H&E, ×40). The synovial membrane of control group (D) is smooth and lined by 1-2 synovial cells (H&E, ×400). In infliximab group (E), synovial membrane is lined by 2-3 cells (arrowhead) and shows moderate degree of chronic inflammation (H&E, ×400). The CFA group (F) shows severe inflammation and marked synovial hyperplasia which shows irregularly piled synovial cells (arrows) (H&E, ×400).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4414638&req=5

Figure 4: Temeporomandibular joint of control (A), infliximab group (B), and CFA group (C) (H&E, ×40). The synovial membrane of control group (D) is smooth and lined by 1-2 synovial cells (H&E, ×400). In infliximab group (E), synovial membrane is lined by 2-3 cells (arrowhead) and shows moderate degree of chronic inflammation (H&E, ×400). The CFA group (F) shows severe inflammation and marked synovial hyperplasia which shows irregularly piled synovial cells (arrows) (H&E, ×400).
Mentions: We analyzed the TMJ histology in the control, infliximab and CFA group. Normal, well preserved synovial lining was observed in the control group. CFA group demonstrated severe inflammation with marked synovial hyperplasia while infliximab group with moderate degree of chronic inflammation (Fig. 4A-F).

Bottom Line: From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05).However, the degree of reduction in BF was less remarkable compared to that in the CFA group.The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea. ; Pain Research Center, School of Medicine, Keimyung University, Daegu, Korea.

ABSTRACT
Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

No MeSH data available.


Related in: MedlinePlus